Society of Gynecologic Oncology
All women with ovarian cancer should have the option of genetic testing, regardless of tumor histology, investigators in a retrospective, tissue-based analysis of a randomized trial concluded.
A higher score on a composite index of homologous recombination deficiency (HRD) correlated with improved progression-free survival (PFS) and overall survival (OS) in ovarian cancer treated with platinum-containing chemotherapy, results of a tissue- based validation study showed.
Results 1 - 2 of 2
